A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Clinical trial NCT03930953 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03930953
- Sponsor
- Celgene
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-20
- Primary completion
- 2027-04-07
- Enrollment
- 438
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.